Preparation and characterization of metformin hydrochloride loaded-Eudragit (R) RSPO and Eudragit (R) RSPO/PLGA nanoparticles

Çetin M., Atila A., Şahin S., Vural İ.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, cilt.18, sa.3, ss.570-576, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3109/10837450.2011.604783
  • Dergi Adı: PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.570-576
  • Anahtar Kelimeler: Eudragit (R) RSPO, metformin hydrochloride, nanoparticles, nanoprecipitation method, PLGA, polymer mixture, DRUG ENTRAPMENT EFFICIENCY, PLGA NANOPARTICLES, IN-VITRO, VIVO EVALUATION, PARTICLE-SIZE, MICROSPHERES, RELEASE, COMBINATION, DELIVERY, FORMULATION
  • Atatürk Üniversitesi Adresli: Evet

Özet

The aim of the present study was to develop and characterize metformin HCl-loaded nanoparticle formulations. Nanoparticles were prepared by the nanoprecipitation method using both a single polymer (Eudragit (R) RSPO) and a polymer mixture (Eudragit/PLGA). The mean particle size ranged from 268.8 to 288 nm and the nanoparticle surface was positively charged (9.72 to 10.1 mV). The highest encapsulation efficiency was observed when Eudragit (R) RSPO was used. All formulations showed highly reproducible drug release profiles and the in vitro drug release in phosphate buffer (pH = 6.8) ranged from 92 to 100% in 12 h. These results suggest that Eudragit (R) RSPO or Eudragit/PLGA nanoparticles might represent a promising sustained-release oral formulation for metformin HCl, reducing the necessity of repeated administrations of high doses to maintain effective plasma concentrations, and thus, increasing patient compliance and reducing the incidence of side-effects.